METHOD FOR PREDICTING THE EFFECTIVENESS OF THE TARGETED THERAPY WITH CETUXIMAB IN THE PATIENTS SUFFERING SQUAMOUS CELL CARCINOMA OF THE TONGUE AND ORAL MUCOSA Russian patent published in 2020 - IPC G01N33/574 G01N33/68 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used to predict the effectiveness of the targeted therapy with cetuximab in the patients with squamous cell carcinoma of the tongue and the oral mucosa. Tumor tissue is examined. After the second course of polychemotherapeutic treatment with inclusion of target therapy of cetuximab in patient with squamous carcinoma of tongue and oral mucosa, tumor trepan biopsy is conducted. In the obtained tumor sample, the level of growth factors VEGF-A and TGF-β, calculating the ratio of VEGF-A/TGF-β. At value of this ratio ≥0.850 high efficiency of cetuximab therapy is predicted. If its value ≤0.384 predict low effectiveness of cetuximab therapy. Values between said intervals are considered to be undefined.

EFFECT: method provides determining the effectiveness of the targeted therapy with cetuximab in the patients with squamous cell and oral mucosa by examining the content of the growth factors VEGF-A and TGF-β in tumor tissue at the stage of polychemotherapeutic treatment – after the second course of polychemotherapy with inclusion of cetuximab.

1 cl, 2 ex